VANDA PHARMACEUTICALS INC. Restructuring Charges
VANDA PHARMACEUTICALS INC. (VNDA) reported Restructuring Charges of $10.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2014-02-25
- VANDA PHARMACEUTICALS INC. restructuring charges for the quarter ending 2013-12-31 was $0.00.
- VANDA PHARMACEUTICALS INC. restructuring charges for the quarter ending 2013-09-30 was $0.00.
- VANDA PHARMACEUTICALS INC. restructuring charges for the quarter ending 2013-06-30 was $0.00.
- VANDA PHARMACEUTICALS INC. restructuring charges for the quarter ending 2013-03-31 was $10.00K, a 99.22% decline year-over-year.
- VANDA PHARMACEUTICALS INC. restructuring charges for fiscal 2013 was $10.00K.
- VANDA PHARMACEUTICALS INC. restructuring charges for fiscal 2012 was -$1.22M.
- VANDA PHARMACEUTICALS INC. restructuring charges for fiscal 2011 was -$740.00K.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month | Restructuring Charges 12 month as first filed |
|---|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $0.00 derived: sum of 2 quarters · filed 2014-02-25 | $0.00 derived: sum of 3 quarters · filed 2014-02-25 | $10.00K 10-K · filed 2014-02-25 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $0.00 derived: sum of 2 quarters · filed 2013-11-08 | $10.00K 10-Q · filed 2013-11-08 | -$2.55M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $10.00K 10-Q · filed 2013-07-31 | -$2.55M derived: sum of 3 quarters · filed 2014-02-25 | ||
| 2013-03-31 | $10.00K 10-Q · filed 2013-05-10 | -$2.55M derived: sum of 2 quarters · filed 2014-02-25 | |||
| 2012-12-31 | -$2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$1.22M 10-K · filed 2014-02-25 | $1.22M 10-K · filed 2013-02-26 | ||
| 2012-09-30 | $1.34M 10-Q · filed 2012-11-08 | ||||
| 2012-03-31 | $1.28M 10-Q · filed 2012-08-03 | $2.02M derived: sum of 2 quarters · filed 2012-11-08 | |||
| 2011-12-31 | $740.00K 10-Q · filed 2012-11-08 | -$740.00K 10-K · filed 2014-02-25 | $740.00K 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |